Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 254 entries
View as:

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

Phase: N/A Priority: Normal
NCT ID: NCT00864474 Org: User:
Start: 03/31/10 End: 12/24/18 Due: 12/24/19

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT04493216 Org: User:
Start: 11/18/20 End: 05/29/23 Due: 05/29/24

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT01803074 Org: User:
Start: 04/04/13 End: 11/29/14 Due: 11/29/15

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Phase: N/A Priority: Normal
NCT ID: NCT02345707 Org: User:
Start: 03/31/15 End: 06/30/15 Due: 06/30/16

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02666053 Org: User:
Start: 01/27/16 End: 02/22/16 Due: 02/22/17

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00098306 Org: User:
Start: 11/30/04 End: 04/30/11 Due: 04/30/12

Fosamprenavir Expanded Access

Phase: N/A Priority: Normal
NCT ID: NCT00240552 Org: User:
Start: 07/31/03 End: 08/31/05 Due: 08/31/06

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Phase: N/A Priority: Normal
NCT ID: NCT00046176 Org: User:
Start: 08/26/02 End: 05/17/04 Due: 05/17/05

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

Phase: N/A Priority: Normal
NCT ID: NCT03754803 Org: User:
Start: 11/08/18 End: 05/06/24 Due: 05/06/25

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Phase: N/A Priority: Normal
NCT ID: NCT00634959 Org: User:
Start: 07/31/03 End: 12/31/03 Due: 12/31/04

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Phase: N/A Priority: Normal
NCT ID: NCT02480894 Org: User:
Start: 07/07/15 End: 09/21/15 Due: 09/21/16

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT03945981 Org: User:
Start: 07/02/19 End: 10/20/20 Due: 10/20/21

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02354937 Org: User:
Start: 07/13/15 End: 11/01/16 Due: 11/01/17

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Phase: N/A Priority: Normal
NCT ID: NCT06134362 Org: User:
Start: 05/24/24 End: 06/26/28 Due: 06/26/29

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

Phase: N/A Priority: Normal
NCT ID: NCT03984825 Org: User:
Start: 06/13/19 End: 08/16/19 Due: 08/16/20

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02185300 Org: User:
Start: 07/31/14 End: 09/30/14 Due: 09/30/15

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT01195974 Org: User:
Start: 09/14/10 End: 02/09/11 Due: 02/09/12

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Phase: N/A Priority: Normal
NCT ID: NCT05896748 Org: User:
Start: 11/08/22 End: 09/14/23 Due: 09/14/24

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Phase: N/A Priority: Normal
NCT ID: NCT05996471 Org: User:
Start: 08/17/23 End: 01/17/29 Due: 01/17/30

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Phase: N/A Priority: Normal
NCT ID: NCT01382238 Org: User:
Start: 06/30/11 End: 08/31/11 Due: 08/31/12

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

Phase: N/A Priority: Normal
NCT ID: NCT02741557 Org: User:
Start: 05/11/16 End: 10/24/16 Due: 10/24/17

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT04900038 Org: User:
Start: 08/18/21 End: 05/11/23 Due: 05/11/24

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Phase: N/A Priority: Normal
NCT ID: NCT04021290 Org: User:
Start: 11/11/19 End: 09/09/22 Due: 09/09/23

Taste Properties of HIV Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02608918 Org: User:
Start: 01/05/16 End: 05/24/16 Due: 05/24/17

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

Phase: N/A Priority: Normal
NCT ID: NCT01231555 Org: User:
Start: 11/18/10 End: 07/04/11 Due: 07/04/12